Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 750.3% from a year ago
Cash & equivalents stood at $9.78M at the end of Q1 FY2026, up 750.3% from a year earlier and up 179.6% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.
Context
- Cash & equivalents amounted to 4.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +750.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 3.5M USD
- Year-over-year change
- -9.3%
- 4-year CAGR
- -47.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.5M | -9.3% |
| FY2024 | 2024-12-31 | 3.86M | -5.7% |
| FY2023 | 2023-12-31 | 4.09M | -24.2% |
| FY2022 | 2022-12-31 | 5.4M | -87.9% |
| FY2021 | 2021-12-31 | 44.44M | — |
Cash & Equivalents vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's Mar 2026 cash & equivalents of $9.78M is the lowest of the 9 companies compared; the peer median is $44.94M.
- Its year-over-year change of +750.3% is the 2nd highest of 9, against a peer median of +28.7%.
- Cash & equivalents amounts to 4.2% of total assets for RLMD, versus a peer median of 36.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $128.06M | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $36.25M | +28.8% | -46.7% | 21.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
CBUSCibus, Inc. | Mar 2026 | $30.33M | +28.6% | +42.5% | 9.4% |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding RLMD) | $44.94M | +28.7% | -8.4% | 36.1% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.44M | 5.4M | 4.09M | 3.86M | 3.5M |
| Short-term Investments | 167.47M | 142.93M | 92.23M | 41.05M | 89.51M |
| Net Receivables | 86.38K | 512.43K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 35 | 0 | 0 | 0 | 0 |
| Total Current Assets | 223.3M | 152.87M | 97.51M | 45.8M | 93.98M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Assets | 223.33M | 152.91M | 97.55M | 45.82M | 94M |
| Account Payables | 11.19M | 5.26M | 3.51M | 4.13M | 1.57M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.64M | 1.02M | 5.68M | 1.15M | 535.48K |
| Total Current Liabilities | 15.06M | 12.47M | 12.19M | 10.29M | 6.43M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Liabilities | 15.06M | 12.47M | 12.19M | 10.3M | 7.49M |
| Common Stock | 27.74K | 30.1K | 30.1K | 30.17K | 73.33K |
| Retained Earnings | (305.07M) | (462.11M) | (560.9M) | (640.88M) | (698.27M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.26M | 140.44M | 85.36M | 35.52M | 86.51M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (44.44M) | (5.4M) | (4.09M) | (3.86M) | (3.5M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.